Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

A Study To Evaluate Methods To Evaluate Back Pain

21 février 2013 mis à jour par: Wyeth is now a wholly owned subsidiary of Pfizer

A Pilot Study To Evaluate Various Methodologies For Assessing The Treatment Of Low Back Pain

The study is designed to assess methods used in clinical research.

Aperçu de l'étude

Statut

Complété

Les conditions

Intervention / Traitement

Type d'étude

Interventionnel

Inscription (Réel)

61

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

  • États-Unis
    • California
      • Loma Linda, California, États-Unis, 92350
        • Pfizer Investigational Site

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 55 ans (Adulte)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Lower back pain
  • Male or female in generally good health, from 18 to 55 years of age (inclusive)

Exclusion Criteria:

  • Pregnant or lactating
  • Subject has evidence or history of radiculopathy, i.e. sciatica extending below the knee (numbness, tingling, or shooting pain), or other neurologic deficits (abnormal straight leg raise test, patellar reflexes, and/or bowel and bladder function);
  • Subject has a history of previous back surgery;
  • Subject has back pain resulting from traumatic injury involving physical evidence of bruising, swelling, or inflammation to the abdomen or low back area which occurred less than 48 hours prior to enrollment
  • Has taken an investigational drug within the past 30 days prior to entering the study, or currently enrolled in another investigational study
  • Is a member or relative of the study site staff, CRO or Sponsor organization directly involved with the study or had a household member or relative participate concurrently or previously in this study
  • Has previously been enrolled in this study

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: 1
Heat device
Dispositif: Heat Device
8-Hour Heatwrap
Autres noms:
  • Heatwrap
Comparateur factice: 2
Placebo arm
Dispositif: Sham Device
Inactive wrap worn for 8 hours
Comparateur actif: 3
Marketed analgesic
Médicament: marketed analgesic
2 x 200 mg ibuprofen tablets
Comparateur placebo: 4
(Oral) Placebo comparator
Médicament: Placebo
2 x placebo tablets

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Time to First Perceptible Relief (Confirmed by Meaningful Relief)
Délai: Baseline (time of wrap application or oral treatment administration) up to 4 hours
"First perceptible relief" defined as the elapsed time from wrap application or oral treatment until the participant depressed the first stopwatch labeled "first perceptible relief" (any pain relieving effect), provided the participant also depressed the second stopwatch labeled "meaningful relief" (meaningful to participant) by the end of the scheduled in-patient evaluation (4 hours / 240 minutes). If the confirmation was not achieved, the participant was censored at the time when the first stopwatch was depressed. Confidence interval (CI) calculated using the method of Simon & Lee.
Baseline (time of wrap application or oral treatment administration) up to 4 hours

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Time to Meaningful Relief
Délai: Baseline (time of wrap application or oral treatment administration) up to 4 hours
Time to "meaningful relief" defined as elapsed time from start of treatment until participant depressed the second stopwatch indicating "meaningful relief" (meaningful to participant). Participant consider censored if participant did not depress the stopwatch by end of 4-hour in-patient evaluation, or became a treatment failure (rescue or discontinuation) during the time prior to depressing the second stopwatch. Censoring was at time of dropout if participant withdrew for non-efficacy related reasons during the 4-hour in-patient portion of the study. CI calculated using method of Simon & Lee.
Baseline (time of wrap application or oral treatment administration) up to 4 hours
Time Weighted Sum of Pain Relief From 0 Through 8 Hours (TOTPAR 0-8)
Délai: Baseline (time of wrap application or oral treatment administration) up to 8 hours
TOTPAR 0-8 sum of pain relief from 0 through 8 hours, weighted by the time duration between the current timepoint and the previous timepoint. Pain relief rated hourly (from baseline) by the participant on a 6-point scale: 0=no relief, 1=a little relief, 2=less than half relief, 3=more than half relief, 4=a lot of relief, 5=complete relief. Total possible score 0 to 40; higher score indicated better relief.
Baseline (time of wrap application or oral treatment administration) up to 8 hours
Time Weighted Sum of Change From Baseline in the Back Stiffness Score Over 8 Hours
Délai: Baseline (time of wrap application or oral treatment administration) up to 8 hours
Time weighted sum of change calculated as sum of change from baseline in back stiffness scores from 0 through 8 hours, weighted by time duration between current timepoint and previous timepoint. Based on hourly (from baseline) back stiffness assessment rating from 0 (no muscle stiffness) to 100 (most possible muscle stiffness). Sum of change derived by subtracting score at post-dosing time point from baseline score. Total possible score -800 to 800; higher positive value was indicative of greater improvement.
Baseline (time of wrap application or oral treatment administration) up to 8 hours
Time to Treatment Failure
Délai: Baseline (time of wrap application or oral treatment administration) up to 8 hours
Time to treatment failure defined as time from dosing to the time of rescue medication within the scheduled duration of the study (8 hours); or for participants who withdrew from the study due to lack of efficacy without taking rescue medication, the time of the last assessment was considered the time to treatment failure; or if participant did not take rescue medication, or did not discontinue due to lack of efficacy, the time to treatment failure was considered censored at 8 hours (the scheduled duration of the study).
Baseline (time of wrap application or oral treatment administration) up to 8 hours
Individual Time-Point Pain Relief Scores
Délai: At 60, 120, 180, 240, 300, 360, 420, and 480 minutes
Pain relief rated hourly (from baseline) by the participant on a 6-point scale: 0=no relief, 1=a little relief, 2=less than half relief, 3=more than half relief, 4=a lot of relief, 5=complete relief.
At 60, 120, 180, 240, 300, 360, 420, and 480 minutes
Change From Baseline in Individual Time-point Back Stiffness Scores
Délai: At 60, 120, 180, 240, 300, 360, 420, and 480 minutes
Low back muscle stiffness rated hourly (from baseline) by the participant by placing a line on a visual analog scale (VAS) from 0 millimeters (mm) to 100 mm in length with 0=no muscle stiffness up to 100 (most possible stiffness).
At 60, 120, 180, 240, 300, 360, 420, and 480 minutes
Change From Baseline (Bsl) in Combined Flexibility Score: Extension
Délai: Baseline (time of wrap application or oral treatment administration) and 4 hours
Flexibility assessed using Paris Plinth table with maximum extension (as if performing a sit-up) of 20 degrees movement. Angle at Bsl and at 4 hours standardized to 100 for assessment of maximum angle (x degrees), x degrees minus 5, and x degrees plus 5. Flexibility score derived using standardized value and VAS score (participant rating of pain by marking level of pain on 100 mm line 0=no pain up to 100=worst pain). Final derived data for extension flexibility were average of the extension flexibility data on the combined score (range -66 to 552); higher value indicated greater improvement.
Baseline (time of wrap application or oral treatment administration) and 4 hours
Change From Baseline (Bsl) in Overall Combined Flexibility Score: Side-to-Side
Délai: Baseline (time of wrap application or oral treatment administration) and 4 hours
Flexibility assessed using Paris Plinth table with maximum side-to-side movement of plus or minus (+/-) 10 degrees for left, and right (L, R), movement. Angle at Bsl and 4 hours standardized to 100 for assessment of maximum angle (x degrees), x degrees - 5, and x degrees + 5. Flexibility score derived using standardized value and VAS score (participant rating of level of pain on 100 mm line 0=no pain to 100=worst pain). Final derived data for overall flexibility was the average of side-to-side (L, R) flexibility data on the combined score (range -81 to 264); higher value=greater improvement.
Baseline (time of wrap application or oral treatment administration) and 4 hours
Change From Baseline (Bsl) in Overall Combined Flexibility Score: Rotation
Délai: Baseline (time of wrap application or oral treatment administration) and 4 hours
Flexibility assessed using Paris Plinth table with maximum rotation at waist of plus or minus (+/-) 30 degrees for left, and right (L, R), movement. Angle at Bsl and at 4 hours standardized to 100 for assessment of maximum angle (x degrees), x degrees - 5, and x degrees + 5. Flexibility score derived using standardized value and VAS score (participant rating of level of pain on 100 mm line 0=no pain up to 100=worst pain). Final derived data for overall flexibility were the average of rotation (L, R) flexibility data on combined score (range -80 to 155); higher value=greater improvement.
Baseline (time of wrap application or oral treatment administration) and 4 hours
Change From Baseline in the Angle Measurement at Maximum Flexion for Flexibility Measures: Extension
Délai: Baseline (time of wrap application or oral treatment administration) and 4 hours
Participant placed in a prone position on Paris Plinth table which is moved at 1 degree per second to maximum movement of 20 degrees for extension (as if performing a sit-up) to the degree of movement at which participant perceives discomfort or pain. Higher score indicated greater improvement.
Baseline (time of wrap application or oral treatment administration) and 4 hours
Change From Baseline in the Angle Measurement at Maximum Flexion for Flexibility Measures: Side-to-Side
Délai: Baseline (time of wrap application or oral treatment administration) and 4 hours
Participant placed in a prone position on Paris Plinth table which is moved at 1 degree per second to maximum movement +/- 10 degrees for left, and right, side-to-side movement to the degree of movement at which participant perceives discomfort or pain. Maximum flexion based on the average of the left and right side-to-side scores. Higher score indicated greater improvement.
Baseline (time of wrap application or oral treatment administration) and 4 hours
Change From Baseline in the Angle Measurement at Maximum Flexion for Flexibility Measures: Rotation
Délai: Baseline (time of wrap application or oral treatment administration) and 4 hours
Participant placed in a prone position on Paris Plinth table which is moved at 1 degree per second to maximum rotation at waist of +/- 30 degrees for left, and right, movement to the degree of movement at which participant perceives discomfort or pain. Maximum flexion based on the average of the left and right rotation scores. Higher score indicated greater improvement.
Baseline (time of wrap application or oral treatment administration) and 4 hours
Change From Baseline (Bsl) in Pain Measurement for Flexibility Measure: Extension
Délai: Baseline (time of wrap application or oral treatment administration) and 4 hours
Flexibility assessed using Paris Plinth table with maximum extension of 20 degrees movement (as if performing a sit-up). When participant feels discomfort or pain, participant places a mark to rate discomfort/pain (maximum) on a VAS of 100 mm in length with 0=no discomfort/no pain up to 100=most discomfort/most pain. Movement decreased 5 degrees (minus) and discomfort rated on VAS. Movement increased 5 degrees (plus) beyond first point when pain was reported and discomfort/pain again rated on the VAS. Higher score indicated greater discomfort/pain.
Baseline (time of wrap application or oral treatment administration) and 4 hours
Change From Baseline in Pain Measurement for Flexibility Measure: Side-to-Side
Délai: Baseline (time of wrap application or oral treatment administration) and 4 hours
Flexibility assessed using Paris Plinth table with maximum side-to-side movement of +/- 10 degrees for L, R movement. When participant feels discomfort or pain, participant places a mark to rate discomfort/pain (maximum) on a VAS of 100 mm in length with 0=no discomfort/no pain up to 100=most discomfort/most pain. Movement decreased 5 degrees (minus) and discomfort rated on VAS. Movement increased 5 degrees (plus) beyond first point when pain was reported and discomfort/pain again rated on the VAS. Analyses based on the average of L, R scores. Higher score indicated greater discomfort/pain.
Baseline (time of wrap application or oral treatment administration) and 4 hours
Change From Baseline in Pain Measurement for Flexibility Measure: Rotation
Délai: Baseline (time of wrap application or oral treatment administration) and 4 hours
Flexibility assessed using Paris Plinth table with maximum rotation at waist of +/- 30 degrees for L, R movement. When participant feels discomfort or pain, participant places a mark to rate discomfort/pain (maximum) on a VAS of 100 mm in length with 0=no discomfort/no pain up to 100=most discomfort/most pain. Movement decreased 5 degrees (minus) and discomfort rated on VAS. Movement increased 5 degrees (plus) beyond first point when pain was reported and discomfort/pain again rated on the VAS. Analyses based on the average of L, R scores. Higher score indicated greater discomfort/pain.
Baseline (time of wrap application or oral treatment administration) and 4 hours
Number of Participants Per Categorical Score for Global Assessment of Study Treatment
Délai: Baseline (time of wrap application or oral treatment administration) up to 8 hours
At hour 8, or at the time of rescue, if it occurred, participants performed a global assessment in their diary in response to the question: How would you rate the study treatment as a pain reliever? Very Poor=0, Poor=1, Fair=2, Good=3, Very Good=4, Excellent=5.
Baseline (time of wrap application or oral treatment administration) up to 8 hours

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Wyeth is now a wholly owned subsidiary of Pfizer

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Liens utiles

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude

1 février 2010

Achèvement primaire (Réel)

1 juillet 2010

Achèvement de l'étude (Réel)

1 juillet 2010

Dates d'inscription aux études

Première soumission

8 janvier 2010

Première soumission répondant aux critères de contrôle qualité

8 janvier 2010

Première publication (Estimation)

11 janvier 2010

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Estimation)

1 avril 2013

Dernière mise à jour soumise répondant aux critères de contrôle qualité

21 février 2013

Dernière vérification

1 février 2013

Plus d'information

Termes liés à cette étude

Mots clés

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • TC-09-20

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner